Navigation Links
AUDIO from Medialink and Genzyme: Study in New England Journal of Medicine Shows Investigational Compound Reduced Relapses and Disability in Patients With MS
Date:10/23/2008

NEW YORK, Oct. 23 /PRNewswire/ -- Phase II clinical trial data appearing in today's issue of the New England Journal of Medicine shows that an investigational compound reduced the effect of multiple sclerosis in comparison to a comparator product, and allowed patients to regain some lost function.

Listen to this report from Genzyme at: http://media.medialink.com/WebNR.aspx?story=35900

Registered journalists can access video, audio, text, graphics and photos for free and unrestricted use at http://www.mediaseed.tv.

09NY08-0120


'/>"/>
SOURCE Medialink and Genzyme
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. AUDIO from Medialink and Radica: Staying Sharp with Games for Your Brain
2. AUDIO from Medialink and Kelloggs: Whats in Your Water?
3. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
4. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
5. AUDIO from Medialink and Pfizer: Prescription for Safer Drugs Discussed in Washington
6. AUDIO from Medialink and Allergan: Women Not Sure Who to Trust on Anti-Aging Skin Care
7. AUDIO from Medialink and Pfizer: A New Prescription for Safer Drugs
8. Audio: New Survey Finds Strong Public Interest in Prescription Drug Safety Issues
9. AUDIO from Medialink and Kelloggs: The Jeans Dont Lie
10. AUDIO from Medialink and Bayer: Simple, Focused Ways to Boost Womens Health
11. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... N.J. , Sept. 12, 2017  Consumer reviews on the ... Hearing as the number one company for hearing aids, ranking ... and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high ...
Breaking Medicine Technology: